Abstract

Haloperydol is a butyrophenone, typical neuroleptic agent characterized as a high antipsychotics effects in the treatment of schizophrenia and in palliative care to alleviation many syndromes, such as naursea, vomiting and delirium. Clinical problems occurs during and after administration of the drug are side effects, particularly extrapyrramidal symptoms (EPS). The neurotoxicity of haloperydol may be initiated by the cationic metabolites of haloperydol, HPP+, RHPP+, formed by oxidation and reduction pathways. These metabolites are transported by human organic cation transporters (hOCT) to several brain structures for exapmle, in substantia nigra, striatum, caudate nucleus, hippocampus. After reaching the dopaminergic neurons inhibits mitochondrial complex I, evidence for free radical involvement, thus leading to neurodegeneration.

References

• 1. Avent K.M., Usuki E., Eyles D.W., Keeve R., Van der Schyf C.J., CastagnoliN. Jr, Pond S.M.: Haloperydol and its tetrahydropyridinederivative (HPTP) are metabolized to potentially neurotoxic pyridiniumspecies in the baboon. Life Sci., 1996; 59: 1473-1482
  Google Scholar
• 2. Balijepalli S., Boyd M.R., Ravindranath V.: Inhibition of mitochondrialcomplex I by haloperydol: the role of thiol oxidation. Neuropharmacology,1999; 38: 567-577
  Google Scholar
• 3. Casey D.E.: Clozapine: neuroleptic-induced EPS and tardive dyskinesia.Psychopharmacology, 1989; 99 (Suppl.): S47-S53
  Google Scholar
• 4. Crowley J.J., Ashraf-Khorassani M., Castagnoli N. Jr., SullivanP.F.: Brain levels of the neurotoxic pyridinium metabolite HPP+ andextrapyramidal symptoms in haloperydol-treated mice. Neurotoxicology,2013; 39: 153-157
  Google Scholar
• 5. Eyles D.W., Avent K.M., Stedman T.J., Pond S.M.: Two pyridiniummetabolites of haloperydol are present in the brain of patients atpost-mortem. Life Sci., 1997; 60: 529-534
  Google Scholar
• 6. Eyles D.W., McGrath J.J., Pond S.M.: Formation of pyridinium speciesof haloperydol in human liver and brain. Psychopharmacology,1996; 125: 214-219
  Google Scholar
• 7. Eyles D.W., McLennan H.R., Jones A., McGrath J.J., Stedman T.J.,Pond S.M.: Quantitative analysis of two pyridinium metabolites ofhaloperydol in patients with schizophrenia. Clin. Pharmacol. Ther.,1994; 56: 512-520
  Google Scholar
• 8. Fang J., Baker G.B., Silverstone P.H., Coutts R.T.: Involvement ofCYP3A4 and CYP2D6 in the metabolism of haloperydol. Cell. Mol.Neurobiol., 1997; 17: 227-233
  Google Scholar
• 9. Fang J., McKay G., Song J., Remillrd A., Li X., Midha K.: In vitrocharacterization of the metabolism of haloperydol using recombinantcytochrome P-450 enzymes and human liver microsomes. DrugMetab. Dispos., 2001; 29: 1638-1643
  Google Scholar
• 10. Forstman A., Larsson M.: Metabolism of haloperydol. Curr. Ther.Res., 1978; 24: 567-568
  Google Scholar
• 11. Gorrod J.W., Fang J.: On the metabolism of haloperydol. Xenobiotica,1993; 23: 495-508
  Google Scholar
• 12. Gründemann D., Babin-Ebell J., Martel F., Ording N., SchmidtA., Schömig E.: Primary structure and functional expression of theapical organic cation transporter from kidney epithelial LLC-PK1cells. J. Biol. Chem., 1997; 272: 10408-10413
  Google Scholar
• 13. Gründemann D., Schechinger B., Rappold G.A., Schömig E.: Molecularidentification of the corticosterone-sensitive extraneuronalcatecholamine transporter. Nat. Neurosci., 1998; 1: 349-351
  Google Scholar
• 14. Hayer-Zillgen M., Brüss M., Bönisch H.: Expression and pharmacologicalprofile of the human organic cation transporters hOCT1,hOCT2 and hOCT3. Br. J. Pharmacol., 2002;136: 829-836
  Google Scholar
• 15. Igarashi K., Kasuya F., Fukui M., Usuki E., Castagnoli N. Jr.:Studies on the metabolism of haloperydol (HP): the role of CYP3Ain the production of the neurotoxic pyridinium metabolite HPP+found in rat brain following ip administration of HP. Life Sci., 1995;57: 2439-2446
  Google Scholar
• 16. Igarashi K., Matsubara K., Kasuya F., Fukui M., Idzu T., CastagnoliN. Jr.: Effect of a pyridinium metabolite derived from haloperydolon the activities of striatal tyrosine hydroxylase in freely movingrats. Neurosci. Lett., 1996; 214: 183-186
  Google Scholar
• 17. Iwahashi K., Anemo K., Nakamura K., Fukunishi I., Igarashi K.:Analysis of the metabolism of haloperydol and its neurotoxic pyridiniummetabolite in patients with drug-induced parkinsonism.Neuropsychobiology, 2001; 44: 126-128
  Google Scholar
• 18. Kang H.J., Lee S.S., Lee C.H., Shim J.C., Shin H.J., Liu K.H., YooM.A., Shin J.G.: Neurotoxic pyridinium metabolites of haloperydolare substrates of human organic cation transporters. Drug Metab.Dispos., 2006; 34: 1145-1151
  Google Scholar
• 19. Kawashima H., Iida Y., Kitamura Y., Kiyono Y., Magata Y., Saji H.:Brain extraction of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridiniumion (HPP+), a neurotoxic metabolite of haloperydol:studies using [3H]HPP+. Jpn. J. Pharmacol., 2002; 89: 426-428
  Google Scholar
• 20. Kawashima H., Iida Y., Kitamura Y., Saji H.: Binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridiniumion (HPP+),a metabolite of haloperydol, to synthetic melanin: implications forthe dopaminergic neurotoxicity of HPP+. Neurotox. Res., 2004; 6:535-542
  Google Scholar
• 21. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H.,Zöchling R., Boissl K.W., Leblhuber F., Riederer P.: Persistence of haloperydolin human brain tissue. Am. J. Psychiatry, 1999; 156: 885-890
  Google Scholar
• 22. Kornhuber J., Wiltfang J., Riederer P., Bleich S.: Neurolepticdrugs in the human brain: clinical impact of persistence and region–specific distribution. Eur. Arch. Psychiatry Clin. Neurosci., 2006;256: 274-280
  Google Scholar
• 23. Korpi E.R., Kleinman J.E., Costakos D.T., Linnoila M., Wyatt R.J.:Reduced haloperydol in the post-mortem brains of haloperydol–treated patients. Psychiatry Res., 1984; 11: 259-269
  Google Scholar
• 24. Lydén A., Larsson B., Lindquist N.G.: Studies on the melaninaffinity of haloperydol. Arch. Int. Pharmacodyn. Ther., 1982; 259:230-243
  Google Scholar
• 25. Maurer I., Möller H.J.: Inhibition of complex I by neuroleptics innormal human brain cortex parallels the extrapyramidal toxicity ofneuroleptics. Mol. Cell. Biochem., 1997; 174: 255-259
  Google Scholar
• 26. Modica-Napolitano J.S., Lagace C.J., Brennan W.A., Aprille J.R.:Differential effects of typical and atypical neuroleptics on mitochondrialfunction in vitro. Arch. Pharm. Res. 2003; 26: 951-959
  Google Scholar
• 27. Murata T., Maruoka N., Omata N., Takashima Y., Igarashi K.,Kasuya F., Fujibayashi Y., Wada Y.: Effects of haloperydol and its pyridiniummetabolite on plasma membrane permeability and fluidityin the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry,2007; 31: 848-857
  Google Scholar
• 28. Nakahara D., Ozaki N., Nagatsu T.: A removed brain microdialysisprobe units for in vivo monitoring of neurochemical activity.Biogenic Amines, 1989; 6: 559-564
  Google Scholar
• 29. Ohman R., Larsson M., Nilsson I.M., Engel J., Carlsson A.: Neurometabolicand behavioural effects of haloperydol in relation to druglevels in serum and brain. Naunyn Schmiedebergs Arch. Pharmacol.,1977; 299: 105-114
  Google Scholar
• 30. Pawłowski M., Westphal Ł., Wesołowska A.: Budowa chemicznai mechanizm działania wybranych leków przeciwpsychotycznych.Czasopismo Aptekarskie, 2009; 10: 54-65
  Google Scholar
• 31. Rollema H., Skolnik M., D’Engelbronner J., Igarashi K., Usuki E.,Castagnoli N. Jr.: MPP(+)-like neurotoxicity of a pyridinium metabolitederived from haloperydol: in vivo microdialysis and in vitromitochondrial studies. J. Pharmacol. Exp. Ther., 1994; 268: 380-387
  Google Scholar
• 32. Sagara Y.: Induction of reactive oxygen species in neurons byhaloperydol. J. Neurochem., 1998; 71: 1002-1012
  Google Scholar
• 33. Shivakumar B.R., Ravindranath V.: Oxidative stress and thiolmodification induced by chronic administration of haloperydol. J.Pharmacol. Exp. Ther., 1993; 265: 1137-1141
  Google Scholar
• 34. Shivakumar B.R., Ravindranath V.: Oxidative stress induced byadministration of the neuroleptic drug haloperydol is attenuated byhigher doses of haloperydol. Brain Res., 1992; 595: 256-262
  Google Scholar
• 35. Someya T., Suzuki Y., Shimoda K., Hirokane G., Morita S., YokonoA., Inoue Y., Takahashi S.: The effect of cytochrome P-450 2D6 genotypeson haloperydol metabolism: a preliminary study in a psychiatricpopulation. Psychiatry Clin. Neurosci., 1999; 53: 593-597
  Google Scholar
• 36. Subramanyam B., Rollema H., Woolf T., Castagnoli N. Jr.: Identificationof a potentially neurotoxic pyridinium metabolite of haloperydolin rats. Biochem. Biophys. Res. Commun., 1990; 166: 238-244
  Google Scholar
• 37. Subramanyam B., Woolf T., Castagnoli N. Jr.: Studies on the invitro conversion of haloperydol to a potentially neurotoxic pyridiniummetabolite. Chem. Res. Toxicol., 1991; 4: 123-128
  Google Scholar
• 38. Tipton K.F., Singer T.P.: Advances in our understanding of themechanisms of the neurotoxicity of MPTP and related compounds.J. Neurochem., 1993; 61: 1191-1206
  Google Scholar
• 39. Ulrich S., Neuhof S., Braun V., Danos P., Pester U., Hoy L.: Dispositionof haloperydol pyridinium and reduced haloperydol pyridiniumin schizophrenic patients: no relationship with clinicalvariables during short-term treatment. J. Clin. Psychopharmacol.,2000; 20: 210-219
  Google Scholar
• 40. Usuki E., Pearce R., Parkinson A., Castagnol N. Jr.: Studies on theconversion of haloperydol and its tetrahydropyridine dehydrationproduct to potentially neurotoxic pyridinium metabolites by humanliver microsomes. Chem. Res. Toxicol., 1996; 9: 800-806
  Google Scholar
• 41. Verhaagh S., Schweifer N., Barlow D.P., Zwart R.: Cloning of themouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifiesa conserved cluster of three organic cation transporters on mousechromosome 17 and human 6q26-q27. Genomics, 1999; 55: 209-218
  Google Scholar
• 42. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., BloomquistJ.R.: Effects of haloperydol metabolites on neurotransmitter uptakeand release: possible role in neurotoxicity and tardive dyskinesia.Brain Res., 1998; 788: 215-222
  Google Scholar
• 43. Wu X., Kekuda R., Huang W., Fei Y.J., Leibach F.H., Chen J., ConwayS.J., Ganapathy V.: Identity of the organic cation transporterOCT3 as the extraneuronal monoamine transporter (uptake2) andevidence for the expression of the transporter in the brain. J. Biol.Chem., 1998; 273: 32776-32786
  Google Scholar

Full text